111¦~1¤ë¥÷³Ì·s°T®§(¤½§i¡B¬F¥O«Å¾É¡BÃÄ«~¦^¦¬)
 

°ê¥ß¶§©ú¥æ³q¤j¾Ç

111/01/14

·q½Ð¨ó§U«Å¶Ç¤Î¹ªÀy¦P¤¯¿ãÅD°Ñ¥[¥»®Õ±À¼s±Ð¨|¤¤¤ß¿ì²z¡u2022¥xÆW¥Í§Þ·sÃIJ£·~¤ÀªR®v¾i¦¨¾Ç¤À¯Z¡v½Òµ{¡A½Ð¬d·Ó¡C

²H¦¿¤j¾Ç¾Ç®Õ°]¹Îªk¤H²H¦¿¤j¾Ç

111/01/04

ÀË°e¥»®Õ¥ø·~ºÞ²z¾Ç¨t111¾Ç¦~«×ºÓ¤h¦b¾±M¯Z©Û¥Í®ü³ø¤Î©Û¥Í¸ê°T¡A½Ð´f¤©¤½§i©Pª¾¨Ã¹ªÀy¶Q³æ¦ì¦P¤¯¿ãÅD³ø¦W¡A½Ð¬d·Ó¡C

»O¥_¥«¬F©²½Ã¥Í§½

111/01/03

¡uºÖ¤ô¶T©ö¦³­­¤½¥q¡vµ¥28®a³c½æ·~ÃÄ°Ó¤ÎÂåÀø¾¹§÷°Ó©Ò»â¥»§½®Öµo¤§³\¥i°õ·Ó¡A·~¸g¥»§½¤½§iµù¾P¡B¼o¤î¦b®×¡A¸Ô¦p»¡©ú¬q¡A½Ð¬d·Ó¡C

111/01/03

¡u¼wôóÂåÀø¾¹§÷ªÑ¥÷¦³­­¤½¥q¡vµ¥21®a³c½æ·~ÃÄ°Ó¤ÎÂåÀø¾¹§÷°Ó©Ò»â¥»§½®Öµo¤§³\¥i°õ·Ó¡A·~¸g¥»§½¤½§iµù¾P¡B¼o¤î¦b®×¡A¸Ô¦p»¡©ú¬q¡A½Ð¬d·Ó¡C

111/01/03

¦³Ãö¥Ý¬ã¬ì§ÞªÑ¥÷¦³­­¤½¥q³q¾]¼t»s³y¤§¡u"¥Ý¬ã"A22¦å²G³zªR²G¡] ½Ã³¡ÃÄ»s¦r²Ä059801¸¹¡^ ¡v¡] §å¸¹¡G A 2010001¡BA2012002¡^ÃÄ«~¦^¦¬¤@®×¡A½Ð¨Ì»¡©ú¬q¿ì²z¡A½Ð¬d·Ó¡C

111/01/04

¬°±À°ÊÃÄ«~¥é³æ¸ê°T¹q¤l¤Æ§@·~¡A½Ã¥ÍºÖ§Q³¡­¹«~ÃĪ«ºÞ²z¸p­q©w¡uÃÄ«~¥H¹q¤lµ²ºc¤Æ¥é³æ¨ú¥N¯È¥»¥é³æ¸Õ¿ì¤è®×¡v¡]¦pªþ¥ó¡^¡A¨Ã¦Û 111¦~1¤ë1¤é°_¸Õ¿ì2¦~¡A´f½ÐÂા©ÒÄÝ·|­ûª¾±x¡A½Ð¬d·Ó¡C

111/01/05

¦³Ãö¡uºÞ¨îÃÄ«~¤À¯Å¤Î«~¶µ¡v­×¥¿¯ó®×¡A·~¸g½Ã¥ÍºÖ§Q³¡©ó¤¤µØ¥Á°ê110¦~12¤ë24¤é¥H½Ã±Â­¹¦r²Ä1101800592¸¹¤½§i¹w§i¡A½Ð¬d·Ó¨ÃÂા©ÒÄÝ·|­û¡C

111/01/12

¥»¥««Ø¿vºÞ²z¤uµ{³B¬°±j¤Æ¥»¥«¤p«¬©ÛµP¼s§iºÞ²z¡A¨ç½ÐÂા©ÒÄÝ¡]ÁÒ¡^·|­û¡A¦p¦³¤p«¬©ÛµP¼s§iÀ³¦V¸Ó³B¥Ó¿ì¼s§iª«³\¥iÃÒ¡A½Ð¬d·Ó¡C

111/01/13

¦³Ãö°ö¤OÃÄ«~¤u·~ªÑ¥÷¦³­­¤½¥q¦^¦¬¡u“°ö¤O”´¶Ã¹¶t¿õ667²@§J ¡]¾L»Ä¶t¡^(½Ã¸pÃÄ»s¦r²Ä036794¸¹)¡v(¦@38§å¡A§å¸¹¸Ô¨£»¡©ú¬q)¤@®×¡A´f½ÐÂા©ÒÄÝ·|­ûª¾±x¡A½Ð¬d·Ó¡C

111/01/14

¦³Ãö¡u¡y°]¹Îªk¤HÃÄ®`±ÏÀÙ°òª÷·|¡z¬°¿ì²z111¦~«×ÃÄ®`±ÏÀÙ·~°È¤§¨ü°U³æ¦ì¡v¤§¤½§i¡A·~¸g½Ã¥ÍºÖ§Q³¡©ó¤¤µØ¥Á°ê111 ¦~1¤ë12¤é¥H½Ã±Â­¹¦r²Ä1101460663¸¹¤½§iµo¥¬¡A´f½ÐÂા©ÒÄÝ·|­ûª¾±x¡A½Ð¬d·Ó¡C

111/01/17

ÀË°e­×¥¿¡uÂå®v¬°«DÀù¯gºC©Ê¹x©T©Ê¯kµh¯f¤Hªø´Á³B¤è¦¨ Å}©Ê³Â¾KÃÄ«~¨Ï¥Î«ü¤Þº[ºÞ²zª`·N¨Æ¶µ¡v1¥÷¡A´f½ÐÂા©ÒÄÝ·|­ûª¾±x¡A½Ð¬d·Ó¡C

111/01/17

¦³Ãö·Å¤h¹yÂåÃĪѥ÷¦³­­¤½¥q¦^¦¬¡u“·Å¤h¹yÈÐÆQ»Ä¥|Àô¯À²´ÃÄ»I (½Ã¸pÃÄ»s¦r²Ä052555¸¹)¡v(§å¸¹TET21005»PTET21036)ÃÄ«~¤@®×¡A½Ð´f¤©Âા©ÒÄÝ·|­ûª¾±x¡A½Ð¬d·Ó¡C

111/01/21

¦³Ãö¶Q·|©ÒÄÝ·|­û«Å¼½©ó¹q¥x¤§¦èÃļs§i¤@®×¡A¸Ô¦p»¡©ú¬q¡A½Ð¬d·Ó¡C

111/01/25

¦³Ãö¡u¦èÃħåµo¹s°â·~­Ó¤H¸ê®ÆÀɮצw¥þºûÅ@­pµe¹ê¬I¿ìªk¡v ³¡¤À±ø¤å¡A·~¸g½Ã¥ÍºÖ§Q³¡©ó¤¤µØ¥Á°ê111¦~1¤ë21¤é¥H½Ã±Â­¹¦r²Ä1101460407¸¹¥O­×¥¿µo¥¬¡A½Ð´f¤©Âા©ÒÄÝ·|­ûª¾±x¡A½Ð¬d·Ó¡C

111/01/26

¦³Ãö¬ìµØ¥Í§ÞÂåÃĪѥ÷¦³­­¤½¥q¸g¾P³c°â¤§¡u©öÄR½§ªwªj²G¡]½Ã¸pÃÄ»s¦r²Ä048746¸¹¡^¡v¡]§å¸¹¡G9300201¡^ÃÄ«~¦^¦¬¤@®×¡A½Ð¨Ì»¡©ú¬q¿ì²z¡A½Ð¬d·Ó¡C

½Ã¥ÍºÖ§Q³¡

111/01/13

¡u¦A¥ÍÂåÀø»s¾¯ºÞ²z±ø¨Ò¡v¨î©w¯ó®×¡A·~¸g¥»³¡©ó¤¤µØ¥Á°ê111¦~1¤ë13¤é¥H½Ã±Â­¹¦r²Ä1101460471¸¹¹w§i¡A½Ð¬d·Ó(¨ÃÂા©ÒÄÝ)¡C

½Ã¥ÍºÖ§Q³¡­¹«~ÃĪ«ºÞ²z¸p

111/01/05

¦³Ãö¶Q¤½¥qÃÄ«~¡u¶PÂù§´¥Ö¤Uª`®g¾¯ 1200/600²@§J¡APhesgo Solution for Subcutaneous Injection 1200/600 mg (½Ã³¡µß¬Ì¿é¦r²Ä001172¸¹¡^¡v¤Î¡u¶PÂù§´¥Ö¤Uª`®g¾¯ 600/600²@§J¡APhesgo Solution for Subcutaneous Injection 600/600 mg (½Ã³¡µß¬Ì¿é¦r²Ä001173¸¹¡^¡v¥Ó½Ð½Õ¾ã¡uÃÄ«~©w´Á¦w¥þ©Ê³ø§i®æ¦¡¤ÎÀË°e®Éµ{¡v¤@®×¡A´_¦p»¡©ú¬q¡A½Ð¬d·Ó¡C

111/01/06

¦³Ãö110-111¦~¦å²G»s¾¯¿é¤J¶q»P¹B¾P¬ö¿ý¡A½Ð¨Ì»¡©ú¬q©ó´Á­­«e´£³ø¥»¸p³Æ¬d¡A½Ð¬d·Ó¡C

111/01/06

¦³Ãö¥»¸p¬ãij¼W¥[¡uÂåÀø¾¹§÷³\¥iÃÒ®Öµo»Pµn¿ý¤Î¦~«×¥Ó³ø·Ç«h¡vªþªí¤T¤§²Ä¤Gµ¥¯ÅÂåÀø¾¹§÷¾A¥Î«~¶µ¤A®×¡A½Ð¨Ìªþ¥ó®æ¦¡´£¨Ñ«Øij«~¶µ¤Îµû¦ô·N¨£¡A¨Ã©ó111¦~3¤ë11¤é«e¨ç´_¥»¸p¡A¹O´Áµø¦PµL·N¨£¡A½Ð¬d·Ó¡C

111/01/13

¶Q¤½¥qÃÄ«~¡uÅKªL³Ç50²@§J ÅK¾¯/²@¤É ª`®g¿éª`²G¡AFerinject 50mg iron/mL solution for Injection /Infusion (½Ã³¡ÃÄ¿é¦r²Ä028140¸¹¡^¡v¦C¤JÃĪ«¦w¥þºÊµø¡A¨äºÊµø´Á¶¡¦Ü115¦~9¤ë24¤é¤î¡A½Ð¬d·Ó¡C

111/01/17

¦³Ãö¶Q¤½¥qÃÄ«~¡uªY«g¯l±aª¬疱¯l¬Ì­]¡AShingrix Herpes Zoster Vaccine (½Ã³¡µß¬Ì¿é¦r²Ä001182¸¹¡^¡v¥Ó½Ð½Õ¾ã¡uÃÄ«~©w´Á¦w¥þ©Ê³ø§i®æ¦¡¤ÎÀË°e®Éµ{¡v¤@®×¡A´_¦p»¡©ú¬q¡A½Ð¬d·Ó¡C

111/01/17

¶Q¤½¥qÃÄ«~¡u§Ù°s§´333²@§J¸z·»¿õ¡AALGLUTOL 333 mg Delayed-Release Tablets (½Ã³¡ÃÄ¿é¦r²Ä028115¸¹¡^¡v¦C¤JÃĪ«¦w¥þºÊµø¡A¨äºÊµø´Á¶¡¦Ü115¦~7¤ë9¤é¤î¡A½Ð¬d·Ó¡C

111/01/18

¦³Ãö¶Q¤½¥qÃÄ«~¡uªA¯á¥ß¤fªA·»²G¥Î¯»¾¯0.75²@§J/²@¤É¡AEVRYSDI Powder for Oral Solution 0.75 mg/mL(½Ã³¡¨uÃÄ¿é¦r²Ä000075¸¹¡^¡v¥Ó½Ð½Õ¾ã¡uÃÄ«~©w´Á¦w¥þ©Ê³ø§i®æ¦¡¤ÎÀË°e®Éµ{¡v¤@®×¡A´_¦p»¡©ú¬q¡A½Ð¬d·Ó¡C

111/01/19

¦³Ãö¶Q¤½¥qÃÄ«~¡uÀù²¦«Ú ª`®g¾¯¡AABEVMY (½Ã³¡µß¬Ì¿é¦r²Ä001156¸¹¡^¡v¥Ó½Ð½Õ¾ã¡uÃÄ«~©w´Á¦w¥þ©Ê³ø§i®æ¦¡¤ÎÀË°e®Éµ{¡v¤@®×¡A´_¦p»¡©ú¬q¡A½Ð¬d·Ó¡C

111/01/19

¦³Ãö¶Q¤½¥qÃÄ«~¡u¾Uªê«ùÄò©ÊÃĮĿõ30²@§J¡ARINVOQExtended-Release Tablets 30mg (½Ã³¡ÃÄ¿é¦r²Ä028174¸¹¡^¡v¥Ó½Ð½Õ¾ã¡uÃÄ«~©w´Á¦w¥þ©Ê³ø§i®æ¦¡¤ÎÀË°e®Éµ{¡v¤@®×¡A´_¦p»¡©ú¬q¡A½Ð¬d·Ó¡C

111/01/20

¦³Ãö¶Q¤½¥qÃÄ«~¡u­¿Àuµøª`®g¾¯120²@§J/²@¤É¡ABeovu 120 mg/mL solution for injection (½Ã³¡µß¬Ì¿é¦r²Ä001174¸¹¡^¡v¥Ó½Ð½Õ¾ã¡uÃÄ«~©w´Á¦w¥þ©Ê³ø§i®æ¦¡¤ÎÀË°e®Éµ{¡v¤@®×¡A´_¦p»¡©ú¬q¡A½Ð¬d·Ó¡C

111/01/27

¡uICH Q6B¡G¥Íª«§Þ³N/¥Íª«ÃÄ«~ÀËÅçµ{§Ç»P¤¹¦¬°ò·Ç¤§³W®æ»Ý¨D(Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products)¡v·~¸g¥»¸p©ó111¦~1¤ë27¤éFDAÃĦr²Ä1111400075A¸¹¤½§i¡A½Ð¬d·Ó¨ÃÂા©ÒÄÝ·|­û¡C

¡@

¡@

¡@

¡@

¡@

¡@

ºô­¶³]­p